Novartis Ag

Simona Cotesta

Vito Guagnano

Andrea Vaupel

Heinrich Rueeger

Jutta Blank

Guido Bold

Robert Mah

Stefan Stutz

Dirk Behnke

Claudia Betschart

Vinod Shashikant Chaudhari

Chetan Pandit

Sangamesh Badiger

Vincent Bordas

Pascal Furet

Bo Tong Liu

Catherine Leblanc

Rainer Machauer

Keiichi Masuya

Marc Gerspacher

Philipp Holzer

Jürgen Wagner

Silvio Ofner

Pascal Rigollier

Achim Schlapbach

Joerg Kallen

Sven Weiler

Edwige Liliane Jeanne Lorthiois

Samuel Hintermann

Bo Liu

Wolfgang Jahnke

Murali Chebrolu

Leo Widler

Jürgen Hans-Hermann Hinrichs

Rainer Wilcken

Christophe Mura

Heinrich Rueger

Nicolas Warin

Nadine Schneider

Jean Michel Rondeau

Arndt Meyer

The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

Pyrazolyl derivatives useful as anti-cancer agents

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 

Imidazopyrrolidine derivatives and their use in the treatment of disease

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the pyrazolo-pyrrolidin-4-one derivatives, and their use as BET inhibitors for the treatment of conditions or diseases such as cancer. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 

Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (1) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. 

Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease

Pyrrolopyrrolone derivatives and their use as BET inhibitors

The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.

Pyrrolopyrrolidinone compounds

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Pyrazolopyrrolidine derivatives and their use in the treatment of disease

The invention relates to compound of the formula (I') in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it. 

Disubstituted heteroaryl-fused pyridines

The invention relates to compound of the formula (I), in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it. 

Diaza-spiro[5.5]undecanes

C-C-Alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula I, wherein one of Rand Ris hydrogen and the other is C-C-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.

[object Object]

Growing community of inventors

Basel, Switzerland

Simona Cotesta